Who is sponsoring NCT06317298?

NCT06317298 is sponsored by Peking University First Hospital.

What drugs are being tested in NCT06317298?

Interventions in NCT06317298: Fruquintinib and Everolimus.

What condition does NCT06317298 study?

NCT06317298 studies Renal Cell Carcinoma, Clear Cell, Somatic.

Is NCT06317298 still recruiting?

NCT06317298 is currently status unknown. Last updated 19 March 2024.

Last reviewed 2024-03-19 · How we verify

NCT06317298

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Status unknown NA Last updated 19 March 2024

What this trial tests

NA trial testing Fruquintinib and Everolimus in Renal Cell Carcinoma, Clear Cell, Somatic in 36 participants. Status unknown.

Timeline

21 February 2024

Primary endpoint
1 August 2025

1 December 2025

Quick facts

Lead sponsor	Peking University First Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	21 February 2024
Primary completion	1 August 2025
Estimated completion	1 December 2025
Sites	1 location across China

Drugs / interventions tested

Fruquintinib and Everolimus — full drug profile →

Conditions studied

Renal Cell Carcinoma, Clear Cell, Somatic — all drugs for Renal Cell Carcinoma, Clear Cell, Somatic →

Sponsor

Peking University First Hospital

Who can join

Adults 18 to 75, any sex, with Renal Cell Carcinoma, Clear Cell, Somatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the efficacy and safety profile of fruquintinib in combination with everolimus as second line therapy of clear cell renal cell carcinoma patients who progressed after immunotherapy and tyrosine kinase inhibitor.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Recent progress on tyrosine kinase inhibitors resistance in renal cell carcinoma: another brick in the wall?
Dong Z, Li S, Li M, Fan M, et al · · 2025 · cited 1× · PMID 41281942 · DOI 10.20517/cdr.2025.157

Verify or expand the search:

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06317298 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 19 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06317298.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing